MedTrace Logo

Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT01409499 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2018-09-11

No results posted yet for this study

Summary

The standard treatment choice for advanced hepatocellular carcinoma (HCC) is sorafenib, and its efficacy is limited. More active treatments were performed in patients with advanced HCC in China, which include radical hepatectomy or TACE. The study is to investigate whether the active treatment will profit survival of patients, and to evaluate the safety.

Conditions

Interventions

PROCEDURE

hepatic resection

palliative hepatectomy followed by sorafenib

PROCEDURE

transcatheter hepatic arterial chemoembolization

TACE followed by sorafenib

DRUG

sorafenib

sorafenib monotherapy, 400mg Bid, continuously

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Minshan Chen, M.D. · Sun Yat-sen University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2017-06-30
Completion
2018-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01409499 on ClinicalTrials.gov